Commercial Momentum FDA approval of NAM-modified stem cell transplant Omisirge demonstrates platform viability and opens direct sales opportunities with allogeneic hematopoietic stem cell transplant programs, major transplant centers, and hospital networks in the United States with potential international expansion.

NAM Platform Opportunity Gamida Cell's NAM technology expands cell numbers while preserving intrinsic properties, enabling scalable manufacturing for cell therapies and potential licensing deals with partners seeking NAM-based manufacturing solutions.

GDA-201 Opportunity The GDA-201 NK cell therapy candidate is in ongoing Phase 1 studies, offering a path to collaborate with oncology centers and academic institutions for trial access and future market adoption alongside NAM-driven manufacturing capabilities.

Commercial Leadership Recent executive hires focused on commercialization signal a concerted go to market strategy for Omisirge, with plans to build field teams, engage transplant centers and distributors, and pursue strategic partnerships.

Diagnostics Synergy A collaboration with ADOR Diagnostics to develop multiplex molecular diagnostics presents cross-selling potential with diagnostics labs and clinics, enabling integrated patient screening or monitoring workflows that complement cell therapy programs.